H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $8 from $7 and keeps a Buy rating on the shares after the company received a strategic investment from Goose Capital and former Tanox CEO Dr. Nancy Chang. The capital provides for an operational runway into Q2 of 2026 for Immix, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX: